Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Health Group's earnings before interest and taxes (EBIT) for the
six
months ended in Mar. 2026 was HK$-38.45 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was HK$-48.67 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
China Health Group's annualizedROC % for the quarter that ended in Mar. 2026 was -50.51%.
China Health Group's annualizedROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -414.81%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
China Health Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -8.92%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Health Group EBIT Related Terms
China Health Group EBIT Historical Data
* Premium members only.
The historical data trend for China Health Group's EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, China Health Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Health Group EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, China Health Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where China Health Group's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-48.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Health Group (HKSE:00673) has a EBIT of HK$-48.67 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on China Health Group.
Is China Health Group's EBIT too high?
China Health Group's current EBIT is HK$-48.67 Mil. Overall, China Health Group has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Health Group's EBIT compare to MCK and COR?
China Health Group's EBIT of HK$-48.67 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Distribution company?
A good EBIT depends on the Medical Distribution industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on China Health Group. China Health Group's current EBIT is HK$-48.67 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Health Group stock overvalued right now?
Based on GuruFocus' analysis, China Health Group (HKSE:00673) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.24, compared to a current price of HK$0.40 — trading 66.7% above its estimated fair value. The current EBIT is HK$-48.67 Mil. China Health Group's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For China Health Group (HKSE:00673), the current EBIT is HK$-48.67 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Health Group (HKSE:00673) Overvalued in 2026?
Based on GuruFocus' analysis, China Health Group stock appears to be overvalued.
The current stock price of HK$0.40 is trading 66.7% above its estimated GF Value™ of HK$0.24.
GuruFocus considers China Health Group to be Significantly Overvalued.
Key valuation signals for HKSE:00673:
EBIT: HK$-48.67 Mil
GF Value™: HK$0.24 vs. price of HK$0.40 (66.7% above fair value)
No single metric tells the full story. See the HKSE:00673 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Health Group Ltd is an investment holding company. It is principally engaged in the distribution and service of medical equipment and consumables, provision of hospital operation and management services, and business factoring. It operates in the business in four segments: medical equipment and consumables distribution and service business; hospital operation and management services business; business service; and research and development and sale of functional food. It derives a majority of revenue from the Distribution and service in the medical equipment and consumables segment. Geographically, the group derives its revenue from the PRC.
24GF Score
Get the complete analysis for HKSE:00673
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00673 has been successfully added to your 
